In vivo neuroimaging data from neuropathological studies show a spatiotemporal development of Aβ deposits in the brain, which originates in the cerebral regions and spreads from the neocortex, to the allocortex, to the brainstem, finally reaching the cerebellum.1,2 Aβ aggregation involves the formation of monomers and oligomers, which then develop into Aβ fibrils and plaques.340 and Aβ42 are the main components of Aβ aggregation, however Aβ42 aggregates into fibrils faster than Aβ40.3 Aβ accumulation in various brain regions results in a cascade of brain damage including abnormal tau phosphorylation, and dysfunction in neuronal physiology (i.e., oxidative stress, mitochondrial dysfunction, neuroinflammation, and impaired brain plasticity).3

References:
1. Hampel H, Hu Y, Hardy J, et al. The amyloid-β pathway in Alzheimer’s disease: a plain language summary. Neurodegener Dis Manag 2023. doi: 10.2217/nmt-2022-0037.

2. Thal DR, Rüb U, Orantes M, Braak H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 2002; 58 (12): 1791–1800.

3. Fišar Z. Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer’s Disease and identifying promising drug targets. Biomolecules 2022; 12 (11): 1676.